预约演示

Roche signs onto Alnylam’s mid-stage hypertension med for $310 million upfront

2023-07-24

交易

临床1期临床2期临床结果临床3期

Alnylam planned to release interim data on hypertension med zilebesiran in the middle of the year.

Alnylams hitching its wagon to Alnylam’s mihypertensionrtenszilebesiranlebesiran, and coughing up $310 million in upfront cash for the journey.

Rocheew partnership gives the SAlnylamarma full ex-hypertensionto thezilebesirano-U.S. rights alongside Alnylam, in exchange for the $310 million plus up to $2.8 billion in potential milestone payments. The two companies will co-commercialize and split profits of the drug in the U.S., according to Monday's announcement.

Alnylam will lead the joint development of the asset through its first indication, currently listed as hAlnylamsion, with both companies splitting costs. Roche will have the opportunity to spearhead the development for any future indications.

Alnylam CEO Yvonne Greenstreet said that the partnership allows Alnylam to “develop zilebesiran in a mohypertensiony,” specifically by having cardiovasculRochetcomes data available at the time of a potential launch.

Alnylamatment is currently in two phase 2 trials, including a plAlnylamontrolled stuzilebesiranzilebesiran in patients with mild to moderate hypertension. Recruitment for that trial—which was aiming to enroll almost 400 participants—wrapped up in February. Patients will receive either zilebesiran or placebo for the first six months of the trial before placebo patients are randomized to one of four potential treatment doses. Alnylam planned to report interim data from the trial midway through the year but has yet to do so.

Another larger phase 2 study is testing zilebesiran as an add-on therapy to Pfizer’s Norvasc, Dzilebesiranyo’s Benicar and indapamide. Recruihypertensionll ongoing in that trial with more than 600 patients expected to be enrolled.zilebesiran Alnylam

Zilebesiran offered a glimmer of promisezilebesiranse 1 results, showing a dPfizerpenNorvascduDaiichi SankyoticBenicarne asindapamideith hypertension and blood pressure control that persisted for up to six months at dose levels of at least 200 mg. The primary endpoint of the monotherapy phase 2 trial is the change from baseline in 24-hour blood pressure at the three-month mark following treatment.

Zilebesiranrves as a significant entry for Roche in the metabolic space, where it has few contenders. The company’s current pipeline listhypertensiontreatment for Pompe disease, as the only clinical-stage metabolic asset.